Aktienanalyse zu Inogen Inc (INGN)INGNInogen Inc

Inogen, Inc. is a global medical technology company offering respiratory products for use in the homecare setting. The Company partners with patients, prescribers, home medical equipment providers, and distributors to make its respiratory therapy products available. It develops, manufactures, and markets respiratory health products, including portable oxygen concentrators (POCs), used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions and the Simeox product for airway clearance treatment. It also distributes the Inogen Voxi 5 stationary oxygen concentrator as well as the Aurora continuous positive airway pressure (CPAP) masks in the United States. Its proprietary Inogen One and Inogen Rove POC systems concentrate the air around the patient to offer a source of supplemental oxygen 24 hours a day, seven days a week with a battery and can be plugged into an outlet when at home, in a car, or in a public place with outlets available. It operates in the Healthcare sector (ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUP industry).

Inogen Inc (INGN) is currently priced at $6.87, which is near its 52-week low of $5.04 and significantly below its 52-week high of $8.29. The company has shown a 20-day change of +15.66%, indicating recent positive momentum. However, the RSI is at 49.49, suggesting that the stock is neither overbought nor oversold. The forward P/E ratio is currently at 0, indicating uncertainty about future earnings, and the gross margin stands at 45.51%, which is relatively strong. The main risk is the negative net income, which was -3.85 million in Q2 2026, highlighting ongoing profitability challenges. Given these factors, it may be prudent to hold rather than buy at this time, waiting for clearer signs of sustained recovery or improvement in profitability.

6 analysts cover INGN: 4 rate it Buy, 2 Hold and 0 Sell. The average price target is 13.00.